ESC 365 - Hospitalization-related costs among patients with atrial fibrillation treated with the factor Xa inhibitor edoxaban vs warfarin: results from the ENGAGE AF-TIMI 48 trial

ESC Premium Access

Hospitalization-related costs among patients with atrial fibrillation treated with the factor Xa inhibitor edoxaban vs warfarin: results from the ENGAGE AF-TIMI 48 trial

Session: Antithrombotic therapy in atrial fibrillation 2

Topic: Atrial fibrillation (AF)

Speaker: Professor E. Magnuson (Kansas City, US)

Event: ESC Congress 2016

Congress Presentation

Add to my library

About the speaker

Professor Elizabeth A Magnuson

Saint Luke's Hospital, Kansas City (United States of America)

0 follower

4 more presentations in this session

Validation of a Modified CHA2DS2-VASc score for stroke risk Stratification in Asian patients with qtrial fibrillation

Speaker: Doctor T. Chao (Taipei, TW)

Temporal change of anticoagulation therapy and its outcomes of Japanese atrial fibrillation patients in the real-world clinical practice: the Fushimi AF Registry.

Speaker: Doctor M. Akao (Kyoto, JP)

Vitamin K antagonist control for patients with nonvalvular atrial fibrillation in Eastern and Southeastern Asia: an analysis of event rates from GARFIELD-AF

Speaker: Professor S. Goto (Isehara, JP)

Reversal strategies and outcomes of major bleeding associated with direct oral anticoagulants compared to warfarin in routine practice: interim results from a multi-centre all-comer cohort

Speaker: Mr Y. Xu (Toronto, CA)

Access the full session

Antithrombotic therapy in atrial fibrillation 2

Speakers: Professor E. Magnuson, Doctor T. Chao, Doctor M. Akao, Professor S. Goto, Mr Y. Xu

About the event

ESC Congress 2016

27 August - 31 August 2016

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources